Skip to main content
. 2022 Oct 20;36(11):2586–2595. doi: 10.1038/s41375-022-01696-w

Fig. 5. A METTL3 inhibitor reverses AML chemoresistance and homing/engraftment capacity.

Fig. 5

A Statistical results showing the improvement of migration (upper) and adhesion (lower) in THP-1/IDA and Kasumi-1/IDA cells can be reversed by STM2457 treatment of 48 h. *P < 0.05, **P < 0.01; ***P < 0.001, NS nonsignificant; t test. B The Statistical analysis of EdU incorporation assay showing the improvement of AML chemoresistance can be reversed by the pretreatment of STM2457. *P < 0.05, **P < 0.01; ***P < 0.001, NS nonsignificant. C The homing and engraftment of THP-1&THP-1/IDA cells with or without STM2457 treatment in the BM and spleen measured by flow cytometry 16 h and 42 days after tail vein injection. *P < 0.05, **P < 0.01; ***P < 0.001, ****P < 0.0001, NS nonsignificant; t test. n ≥ 3, mean ± SD values are shown for (A–C).